Heska Corporation (HSKA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Heska Corporation (HSKA) trades at $119.99 with AI Score 50/100 (Grade B). Heska Corporation provides veterinary diagnostic and specialty products, primarily for canine and feline health. Market cap: $1.31B, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 10, 2026Analyst Coverage for HSKA: HSKA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HSKA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HSKA: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Heska Corporation (HSKA) Healthcare & Pipeline Overview
Heska Corporation focuses on the veterinary diagnostics market, offering a comprehensive suite of point-of-care diagnostic instruments, consumables, and services for companion animals. With a global presence and a focus on innovation, Heska aims to improve veterinary care through advanced diagnostic solutions, though it currently operates with a negative profit margin.
What Is the Investment Thesis for HSKA?
Heska Corporation operates in the growing veterinary diagnostics market, driven by increasing pet ownership and rising demand for advanced veterinary care. The company's comprehensive product portfolio and global presence provide a solid foundation for future growth. Key value drivers include expanding its installed base of diagnostic instruments, increasing consumable sales, and leveraging its distribution network. The company's negative profit margin of -7.2% requires careful monitoring and improvement. Upcoming catalysts include potential new product launches and expansion into new geographic markets. However, investors should be aware of risks such as competition from larger players and potential regulatory changes.
Based on FMP financials and quantitative analysis
HSKA Key Highlights
- Market capitalization of $1.31B, reflecting investor valuation of its market position.
- Gross margin of 43.2%, indicating the profitability of its core product offerings before operating expenses.
- Operates with a negative profit margin of -7.2%, signaling potential concerns about operational efficiency and cost management.
- Beta of 1.60, suggesting higher volatility compared to the overall market.
- No dividend yield, indicating that the company is reinvesting earnings for growth.
Who Are HSKA's Competitors?
HSKA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. | $539.37 | -1.03% | $42.6B | 94 |
| ZTS Zoetis Inc. | $74.57 | +0.51% | $31.3B | 86 |
| CNMD CONMED Corporation | $41.27 | -1.74% | $1.24B | 76 |
| AORT Artivion Inc. | $25.00 | -0.56% | $1.21B | 61 |
| IRMD IRadimed Corporation | $93.86 | -0.23% | $1.20B | 97 |
| INSP Inspire Medical Systems, Inc. | $50.81 | +0.81% | $1.46B | 95 |
| SILK Silk Road Medical, Inc | $27.49 | -0.04% | $1.12B | 60 |
| LFTSF LifeTech Scientific Corporation | $0.23 | +0.00% | $1.03B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HSKA's Key Strengths?
- Comprehensive product portfolio of diagnostic instruments and consumables
- Established relationships with veterinary clinics
- Global distribution network
- Focus on innovation and new product development
What Are HSKA's Weaknesses?
- Negative profit margin
- Smaller market share compared to larger competitors
- Dependence on consumable sales for recurring revenue
- High beta indicating higher volatility
What Could Drive HSKA Stock Higher?
- Potential new product launches in diagnostic instruments and consumables.
- Expansion into new geographic markets, particularly in Asia and South America.
- Increasing demand for point-of-care diagnostics in veterinary clinics.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
What Are the Key Risks for HSKA?
- Negative return on equity (-4.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger players with greater resources.
- Regulatory changes in the animal health industry.
- Economic downturn affecting pet ownership and veterinary spending.
- Dependence on consumable sales for recurring revenue.
- Negative profit margin requiring improvement in operational efficiency.
What Are the Growth Opportunities for HSKA?
- Expansion of Point-of-Care Diagnostics: Heska can capitalize on the increasing demand for point-of-care diagnostics in veterinary clinics. The global point-of-care diagnostics market is projected to reach $40 billion by 2028. By expanding its range of in-clinic diagnostic instruments and consumables, Heska can capture a larger share of this market. This includes developing new tests and improving the speed and accuracy of existing instruments, providing veterinarians with faster and more reliable results, leading to better patient outcomes.
- Geographic Expansion: Heska has the opportunity to expand its presence in international markets, particularly in Asia and South America, where pet ownership is growing rapidly. By establishing distribution partnerships and tailoring its product offerings to local needs, Heska can tap into new revenue streams. The global veterinary healthcare market is expected to reach $75 billion by 2027, with emerging markets contributing significantly to this growth. This expansion could involve direct sales operations or collaborations with local distributors.
- Development of New Diagnostic Tests: Investing in research and development to create new diagnostic tests for emerging animal diseases can drive growth. The market for specialized veterinary diagnostics is expanding as new diseases emerge and awareness of animal health issues increases. Heska can focus on developing tests for specific conditions or species, creating a niche market for its products. This includes leveraging advanced technologies such as molecular diagnostics and genomics to develop more accurate and sensitive tests.
- Strategic Partnerships and Acquisitions: Heska can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By partnering with other companies in the animal health industry, Heska can gain access to new technologies, products, and distribution channels. Acquisitions can also provide Heska with a competitive advantage by consolidating market share and expanding its customer base. These partnerships can range from joint development agreements to co-marketing arrangements.
- Subscription-Based Service Model: Transitioning to a subscription-based service model for its diagnostic instruments and consumables can generate recurring revenue and improve customer loyalty. By offering subscription packages that include instrument maintenance, software updates, and consumable supplies, Heska can create a more predictable revenue stream and strengthen its relationships with veterinary clinics. This model can also provide Heska with valuable data on instrument usage and customer needs, allowing it to tailor its product offerings and services more effectively.
What Opportunities Does HSKA Have?
- Expansion of point-of-care diagnostics
- Geographic expansion into emerging markets
- Development of new diagnostic tests for emerging diseases
- Strategic partnerships and acquisitions
What Threats Does HSKA Face?
- Competition from larger players with greater resources
- Potential regulatory changes in the animal health industry
- Economic downturn affecting pet ownership and veterinary spending
- Technological advancements rendering existing products obsolete
What Are HSKA's Competitive Advantages?
- Proprietary diagnostic technologies
- Established relationships with veterinary clinics
- Comprehensive product portfolio
- Global distribution network
What Does HSKA Do?
Founded in 1988 as Paravax, Inc., Heska Corporation rebranded in 1995 to focus on the animal health market. The company develops, manufactures, and markets veterinary diagnostic and specialty products, primarily for canine and feline healthcare. Heska's product portfolio includes a range of diagnostic instruments such as blood chemistry analyzers (Element DC, Element RC), hematology analyzers (Element HT5), blood gas and electrolyte analyzers (Element POC), and immunodiagnostic analyzers (Element i). These instruments are designed for in-clinic use, providing veterinarians with rapid and accurate diagnostic results. In addition to instruments, Heska offers a variety of consumables, including reagents, test kits, and other supplies. The company also provides related services, such as HeskaView Telecytology, IV infusion pumps, digital radiography, ultrasound systems, and Cloudbank, a Web-based image storage solution. Heska's products are sold to veterinarians through a direct sales force, third-party distributors, and strategic partnerships across the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Heska also offers Tri-Heart Plus chewable tablets for heartworm prevention and ALLERCEPT allergy products and services. Furthermore, Heska provides bovine vaccines and turnkey services to other animal health companies.
What Products and Services Does HSKA Offer?
- Develops and markets veterinary diagnostic instruments.
- Offers blood chemistry and hematology analyzers for in-clinic use.
- Provides immunodiagnostic and blood gas analyzers.
- Sells consumables such as reagents and test kits.
- Offers telecytology and digital radiography solutions.
- Provides allergy products and services, including allergen panels and therapy.
- Manufactures and distributes heartworm prevention medication (Tri-Heart Plus).
- Offers bovine vaccines and turnkey services to other animal health companies.
How Does HSKA Make Money?
- Sells diagnostic instruments to veterinary clinics.
- Generates recurring revenue through consumable sales (reagents, test kits).
- Provides related services such as telecytology and digital radiography.
- Distributes products through a direct sales force and third-party distributors.
What Industry Does HSKA Operate In?
The veterinary diagnostics market is experiencing robust growth, driven by increasing pet ownership, rising disposable incomes, and a greater emphasis on preventative care for animals. This market is characterized by technological advancements in diagnostic instruments and a growing demand for point-of-care testing. Heska competes with larger players in the industry, such as Zoetis and IDEXX Laboratories, by focusing on specialized diagnostic solutions and building strong relationships with veterinary clinics. The industry is expected to continue growing at a steady pace, presenting opportunities for Heska to expand its market share and improve its financial performance.
Who Are HSKA's Key Customers?
- Veterinary clinics and hospitals
- Animal health companies
- Veterinarians
- Research institutions
F-Score 3/9Financial Health
Heska Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.78 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -4%Key Financial Metrics
Return on equity for Heska Corporation stands at -4.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.5%, the inverse of the P/E and a quick read on earnings relative to price.
Heska Corporation (HSKA) Valuation Context
Valued at $1.31B, HSKA is classified as a small-cap stock. Relative to its peer group, HSKA's quantitative score of 50/100 is below the peer average of 83/100.
HSKA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Heska's growth potential, as executives are investing their own money.
- The veterinary diagnostics market is experiencing expansion, and Heska's innovative products position it well to capture market share.
- Community sentiment has turned positive, with discussions highlighting the company's strong pipeline and upcoming product launches.
- Heska's strategic partnerships are enhancing its distribution capabilities, making its offerings more accessible to veterinary practices.
Bear Case
- Concerns about market competition are rising, with new entrants threatening Heska's market position in veterinary diagnostics.
- Recent earnings reports have shown slower growth, leading to skepticism among investors regarding future performance.
- Social sentiment has seen some bearish discussions, particularly around the company's ability to maintain margins amid rising costs.
- Regulatory hurdles in the veterinary sector could impact Heska's ability to bring new products to market in a timely manner.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
HSKA Latest News
No recent news available for HSKA.
HSKA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSKA.
Price Targets
Wall Street price target analysis for HSKA.
HSKA MoonshotScore
What does this score mean?
The MoonshotScore rates HSKA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kevin S. Wilson
CEO
Kevin S. Wilson has served as the CEO of Heska Corporation, bringing extensive experience in the animal health industry. His background includes leadership roles in various healthcare and veterinary companies, focusing on strategic growth and operational efficiency. Wilson's expertise spans product development, marketing, and sales, with a strong emphasis on building customer relationships and driving innovation. He holds advanced degrees in business and veterinary science, providing a comprehensive understanding of the animal health market.
Track Record: Under Kevin S. Wilson's leadership, Heska Corporation has expanded its product portfolio and geographic reach. Key achievements include the launch of new diagnostic instruments and the establishment of strategic partnerships to enhance distribution. Wilson has also focused on improving operational efficiency and driving revenue growth. His tenure has been marked by a commitment to innovation and customer satisfaction, positioning Heska as a leading provider of veterinary diagnostic solutions.
What Investors Ask About Heska Corporation (HSKA) — Healthcare
What does the AI Score mean for HSKA?
HSKA holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Heska Corporation provides veterinary diagnostic and specialty products, primarily for canine and feline health. The company operates in the United States and internationally, offering a range …
What does Heska Corporation do?
Heska Corporation is a global provider of veterinary diagnostic and specialty products, primarily focused on canine and feline healthcare. The company develops, manufactures, and markets a range of diagnostic instruments, including blood chemistry analyzers, hematology analyzers, and immunodiagnostic analyzers. Additionally, Heska offers consumables such as reagents and test kits, as well as related services like telecytology and digital radiography.
What do analysts say about HSKA stock?
Analyst consensus on Heska Corporation (HSKA) reflects a mixed outlook, with some citing the company's growth potential in the veterinary diagnostics market as a positive factor. Key valuation metrics, such as price-to-sales ratio, are being closely monitored. Growth considerations include the company's ability to expand its market share, improve its profit margin, and successfully launch new products.
What are the main risks for HSKA?
Heska Corporation faces several risks, including intense competition from larger companies like IDEXX Laboratories and Zoetis, which have greater resources and market share. Regulatory changes in the animal health industry could also impact the company's operations and profitability. Economic downturns could reduce pet ownership and veterinary spending, affecting Heska's revenue.
What are the key factors to evaluate for HSKA?
Heska Corporation (HSKA) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does HSKA data refresh on this page?
HSKA's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HSKA's recent stock price performance?
Heska Corporation (HSKA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio of diagnostic instruments and consumables. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HSKA overvalued or undervalued right now?
Heska Corporation (HSKA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HSKA before investing?
Before investing in Heska Corporation (HSKA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and market analysis as of 2026-05-10.
- Financial metrics are subject to change based on future performance.